Core Insights - Robertet is investing in Aethera Biotech to enhance its capabilities in plant-based biotechnologies, with a joint venture planned to be 50-50 owned by both companies in the long term [1][2] Group 1: Investment Details - The investment in Aethera Biotech will occur in two phases over three years, contingent on undisclosed market conditions [1] - Financial terms of the deal have not been disclosed [1] Group 2: Company Background - Aethera Biotech, founded in 2016 and based in Camisano Vicentino, Italy, specializes in producing active ingredients for the cosmetic and health markets through cell multiplication processes [3] - Aethera is a subsidiary of Cereal Docks Group, which focuses on primary agro-food transformation [3] Group 3: Biotechnology Strategy - The partnership aims to develop advanced cosmetic active ingredients, reflecting a targeted biotech strategy [2] - Aethera's proprietary CROP platform allows for the secure production of natural extracts in controlled conditions, independent of external factors [4] Group 4: Environmental Impact - The CROP platform significantly reduces environmental impact and offers a sustainable alternative to traditional production methods, embodying the concept of 'Augmented Naturality' [5] - This collaboration enables Robertet to strengthen its biotechnology expertise and secure sustainable access to innovative natural ingredients [6] Group 5: Leadership and Future Outlook - The joint venture aligns with Robertet's ambition to reinforce its leadership in natural ingredients and explore new pathways for innovation and growth [7]

Core Insights - Interparfums, Inc. (IPAR) reported strong sales results for Q4 2025, driven by holiday demand, favorable foreign exchange effects, and momentum across core fragrance brands [1][2]. Sales Performance - For Q4 2025, Interparfums achieved a 7% increase in net sales, reaching $386 million, marking its best-ever fourth-quarter performance. Full-year net sales reached a record $1.489 billion, supported by currency tailwinds and growth across a broad portfolio of prestige and luxury fragrance brands [2]. - Europe-based net sales were $233 million in Q4, a 9% increase from the prior period, including 4% organic growth and a 4% benefit from foreign exchange. Full-year European sales rose 7% compared to 2024 on a reported basis and 4% organically [3]. Brand Contributions - Coach fragrances posted 5% growth in Q4 and 15% for the full year, supported by established lines and new launches [4]. - Lacoste fragrances saw strong gains of 23% in Q4 and 28% for the full year, with annual sales reaching $108 million [4]. - Montblanc fragrances recorded 22% growth in Q4, supported by the launch of the Montblanc Explorer Extreme line [5]. - Jimmy Choo fragrances grew 6% in 2025, driven by sustained demand in the U.S. market [5]. U.S. Sales Metrics - In Q4 2025, U.S.-based net sales reached $155 million, indicating a 4% year-over-year increase, supported by growth from GUESS and Donna Karan/DKNY [7]. - For the full year, U.S. sales totaled $482 million, a 6% decline from $511 million in 2024. Excluding the impact of the discontinued Dunhill license, the decline was 3% [7]. - GUESS and Donna Karan/DKNY returned to growth with 7% and 8% increases, respectively, in Q4 [8]. - Roberto Cavalli fragrances delivered significant gains, with sales rising 33% in both Q4 and the full year [9]. - MCM fragrances recorded growth of 40% in Q4 and 17% for the full year [9]. Strategic Initiatives - Interparfums' growth strategy focuses on brand elevation, consistent innovation, and disciplined portfolio management. The company is investing in marketing and advertising to enhance brand desirability while expanding digital and travel retail channels [11]. - Despite macroeconomic challenges, Interparfums ended 2025 with market share gains and record annual sales, entering 2026 with cautious optimism and plans for new product innovation [12].